HealthcareServices

Global Neurogenomics Market Set for Strong Expansion, Reaching $2.98 Billion With 14.7% CAGR by 2030

February 27, 2026 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the neurogenomics market from 2026–2035 with trusted insights from The Business Research Company

What total market size is anticipated for the Neurogenomics Market in 2030?_x000D_

The neurogenomics market has experienced substantial growth recently. This market is projected to expand from $1.5 billion in 2025 to $1.72 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 14.7%. Factors contributing to this historical growth include advancements in genomic sequencing technologies, an increase in neuroscience research funding, the rising prevalence of neurological disorders, enhanced availability of bioinformatics tools, and a surge in academic research collaborations._x000D_

_x000D_

The neurogenomics market is anticipated to experience significant expansion over the next few years, projected to attain a valuation of $2.98 billion by 2030, progressing at a compound annual growth rate (CAGR) of 14.7%. This projected growth stems from several factors, including the increasing integration of genomics within clinical neurology, rising investments in precision neurology, the expansion of cloud-based genomic analytics, a growing demand for personalized neurological therapies, and an increasing focus on translational neuroscience research. Concurrently, major trends expected during this period encompass the increasing adoption of next-generation sequencing in neuroscience, the rising use of multi-omics data integration, a growing demand for gene expression analysis in neurology, the expansion of personalized neurological research, and an enhanced focus on data-driven studies of brain disorders._x000D_

_x000D_

#Access Your Free Sample Report for In-Depth Market Insights:#_x000D_

https://www.thebusinessresearchcompany.com/sample.aspx?id=25845&type=smp_x000D_

_x000D_

What Drivers Are Influencing Production Trends In The Neurogenomics Market?_x000D_

The neurogenomics market is anticipated to expand due to the increasing incidence of neurological disorders. These conditions are defined as medical ailments affecting the brain, spinal cord, or nerves, leading to symptoms such as muscle weakness, seizures, pain, or cognitive difficulties. The escalating occurrence of neurological disorders is primarily linked to lifestyle factors including poor diet, lack of physical activity, chronic stress, and growing exposure to environmental toxins. Neurogenomics provides a more profound understanding of the genetic underpinnings of brain function and dysfunction, thereby enabling the identification of causes, improved diagnosis, and targeted treatments for these disorders. For instance, in March 2023, according to the Alzheimer’s Association, a US-based nonprofit voluntary health organization, approximately 6.7 million Americans aged 65 and older were living with Alzheimer’s dementia, and this figure is projected to rise to 13.8 million by 2060. Therefore, the expanding prevalence of neurological disorders is driving the growth of the neurogenomics market._x000D_

_x000D_

Which Segment Groups Are Influencing The Neurogenomics Market?_x000D_

The neurogenomics market covered in this report is segmented –_x000D_

_x000D_

1) By Offering: Next-Generation Sequencing, Polymerase Chain Reaction, Microarray, Software And Services_x000D_

2) By Application: Variant Discovery, Research Applications, Target Identification, Transcription Factor Binding Analysis, Functional Studies, Clinical Applications_x000D_

3) By End User: Pharmaceutical And Biotechnology Companies, Academic And Research Institutes, Hospitals And Diagnostic Laboratories_x000D_

_x000D_

Subsegments:_x000D_

1) By Next-Generation Sequencing: Whole Genome Sequencing, Whole Exome Sequencing, Targeted Sequencing, Ribonucleic Acid Sequencing_x000D_

2) By Polymerase Chain Reaction: Real-Time Polymerase Chain Reaction, Reverse Transcription Polymerase Chain Reaction, Digital Polymerase Chain Reaction_x000D_

3) By Microarray: Deoxyribonucleic Acid Microarray, Ribonucleic Acid Microarray, Protein Microarray_x000D_

4) By Software And Services: Data Analysis And Interpretation Software, Genomic Data Management Tools, Custom Services, Cloud-Based Platforms And Reporting Tools_x000D_

_x000D_

Which Trends Are Influencing The Development Of The Neurogenomics Market?_x000D_

Leading companies in the neurogenomics market are concentrating on developing sophisticated tools, such as whole genome sequencing platforms, to improve the diagnosis and comprehension of intricate neurological conditions. These platforms serve as instruments for scrutinizing an individual’s entire DNA sequence, thereby assisting in the identification of genetic elements associated with neurological disorders. As an illustration, in April 2023, Centogene N.V., a German firm specializing in the diagnosis and research of rare diseases, introduced CentoGenome. This solution is recognized as the world’s most extensive whole-genome sequencing offering for diagnosing both rare and neurodegenerative diseases. It leverages PCR-free technology to facilitate high-quality, unbiased sequencing across challenging genetic areas. The platform enhances the detection of genetic variations through its advanced bioinformatics pipeline and expert analysis, capable of identifying almost all disease-causing variants in a single examination. Furthermore, it provides continuous diagnostic assistance throughout a patient’s life, including complimentary variant reclassification and follow-up testing as new scientific insights emerge._x000D_

_x000D_

Who Are The Core Companies Influencing Trends In The Neurogenomics Market?_x000D_

Major companies operating in the neurogenomics market are F. Hoffmann-La Roche Limited, Thermo Fisher Scientific Incorporated, Danaher Corporation, Eurofins Scientific SE, Agilent Technologies Inc., Illumina Inc., Revvity Inc., QIAGEN N.V., Myriad Genetics Inc., GeneDx LLC, Fulgent Genetics Inc., Oxford Nanopore Technologies Plc, PacBio, MedGenome Labs Ltd., MGI Tech Co. Ltd., Centogene N.V., Variantyx Inc., BGI Genomics Co. Ltd., GenScript Biotech Corporation, Roche Diagnostics GmbH, Illumina Cambridge Ltd._x000D_

_x000D_

#Access The Complete Report For Deeper Market Insights:#_x000D_

https://www.thebusinessresearchcompany.com/report/neurogenomics-global-market-report_x000D_

_x000D_

Which Region Is Expected To Experience The Fastest Growth In The Neurogenomics Market?_x000D_

North America was the largest region in the neurogenomics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the neurogenomics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa._x000D_

_x000D_

#Request Your Customized Neurogenomics Market Research Report for Competitive Advantage:#_x000D_

https://www.thebusinessresearchcompany.com/customise?id=25845&type=smp_x000D_

_x000D_

#Browse Through More Reports Similar to the Global Neurogenomics Market 2026, By The Business Research Company#_x000D_

_x000D_

Neuroscience Market Report 2026_x000D_

https://www.thebusinessresearchcompany.com/report/neuroscience-global-market-report_x000D_

_x000D_

Genomics Market Report 2026_x000D_

https://www.thebusinessresearchcompany.com/report/genomics-global-market-report_x000D_

_x000D_